◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

科华生物

科华生物
Loading...
Price History
Market Data
Market Cap3.0B
Market Cap (USD)$407.9M
P/E Ratio-
P/B Ratio-
EPS-1.27
Dividend Yield-
D/E Ratio0.31
Current Ratio3.46
Market SegmentSME
CurrencyCNY
Business Overview

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.

证监会行业分类 C27医药制造业 SZSE
Key Financial Metrics
1.8B
Revenue
-731.0M
Net Income
-1.27
EPS (Diluted)
-305.1M
Free Cash Flow
Profitability
Gross Margin -
Operating Margin -41.3%
Net Profit Margin -41.6%
EBITDA -727.0M
Returns & Efficiency
Return on Assets (ROA) -14.0%
Return on Equity (ROE) -18.4%
Dividend Yield -
EPS -1.27
Financial Health
Total Assets 5.2B
Total Debt 1.3B
Debt to Equity 0.31x
Current Ratio 3.46
Company Info
IndustryC27医药制造业
Market SegmentSME
CurrencyCNY
Fiscal Year2024
Peers
2.7T
P/E: 7.6
2.5T
P/E: 7.2
2.4T
P/E: 8.7
CNOOC LIMITED
600938
2.0T
P/E: 16.2
1.9T
P/E: 25.6
1.8T
P/E: 20.1
1.8T
P/E: 7.3
1.2T
P/E: 6.9
Stock Chart
Open Full Chart View

Full charting with technical indicators, candlestick, line charts, and more.

Company Profile
General Information
Company Name科华生物
Ticker002022
ExchangeSZSE
Sector证监会行业分类
IndustryC27医药制造业
Market SegmentSME
Fiscal Year2024
CurrencyCNY
Financial Summary
Market Cap3.0B
Market Cap (USD)$407.9M
Revenue1.8B
Net Income-731.0M
P/E Ratio-
EPS-1.27
Net Margin-41.6%
ROE-18.4%
Dividend Yield-
Description

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...